APA (7th ed.) Citation

Weickhardt, A., Frentzas, S., Lemech, C., Srimani, J., Yin, J., Trepicchio, W., . . . Kichenadasse, G. (2023). 711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. Annals of Oncology, 34, S492. https://doi.org/10.1016/j.annonc.2023.09.1897

Chicago Style (17th ed.) Citation

Weickhardt, A.J, S. Frentzas, C. Lemech, J. Srimani, J. Yin, W.L Trepicchio, C. Gorgun, and G. Kichenadasse. "711TiP A Phase I/II, First-in-human, Open-label, Dose-escalation Study of TAK-186, an EGFR × CD3ε COBRA T Cell Engager, in Adult Patients with Unresectable, Locally Advanced, or Metastatic Solid Tumors." Annals of Oncology 34 (2023): S492. https://doi.org/10.1016/j.annonc.2023.09.1897.

MLA (9th ed.) Citation

Weickhardt, A.J, et al. "711TiP A Phase I/II, First-in-human, Open-label, Dose-escalation Study of TAK-186, an EGFR × CD3ε COBRA T Cell Engager, in Adult Patients with Unresectable, Locally Advanced, or Metastatic Solid Tumors." Annals of Oncology, vol. 34, 2023, p. S492, https://doi.org/10.1016/j.annonc.2023.09.1897.